Drug-Eluting Stent
BIODEGRADE: Cobalt-chromium DES noninferior to stainless steel DES for ACS
IVUS-XPL: In long lesions, IVUS-guided PCI retains superior outcomes at 5 years
Pharmacotherapy highlights from TCT: TWILIGHT, Onyx ONE and more
Another study finds no evidence of increased long-term mortality with paclitaxel-coated devices
BLADE-PCI: Novel liposomal alendronate fails in diabetes
EXCEL: PCI ‘acceptable revascularization modality’ for left main CAD at 5 years
PAD Awareness Month: Five recent updates
MODEL U-SES: 3-month DAPT noninferior to standard DAPT after PCI with bioresorbable SES
Durable-polymer DES noninferior to polymer-free DCS in patients with high bleeding risk, shorter DAPT: Onyx ONE

SAN FRANCISCO — In the first randomized trial to compare a durable-polymer DES with a polymer-free drug-coated stent in patients with high bleeding risk who received 1 month of dual antiplatelet therapy, treatment with the DES was as safe and effective as treatment with the DCS, according to results of the Onyx ONE trial presented at TCT 2019.
TWILIGHT: Switching to ticagrelor monotherapy 3 months post-PCI lowers bleeding vs. DAPT

SAN FRANCISCO — Among patients who had PCI with a drug-eluting stent and were on dual antiplatelet therapy for 3 months, subsequent ticagrelor monotherapy lowered bleeding risk without raising ischemic risk compared with continued DAPT, according to results of the TWILIGHT trial presented at TCT 2019.